Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ARWR · as of Mar 31, 2025
Ownership Breakdown
280
Institutional Holders
▼ 9 vs Q4
$1.34B
Total Inst. Value
▼ $535.28M vs Q4
140.86M
Shares Outstanding
freeFloat 87.17%
105.25M
13F Shares Held
▲ 5.42M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ARWR largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 19.93M | 14.82% | 14.82% | $253.86B | May 2, 2025 | ▲ 3.75M |
VANGUARD GROUP INC pharmaceutical preparations | 13.20M | 9.82% | 9.82% | $168.20B | May 9, 2025 | ▲ 1.02M |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 11.11M | 8.26% | 8.26% | $141.56B | May 15, 2025 | — held |
STATE STREET CORP pharmaceutical preparations | 7.00M | 5.20% | 5.20% | $89.17B | May 15, 2025 | ▲ 983.0K |
SLATE PATH CAPITAL LP pharmaceutical preparations | 5.23M | 3.89% | 3.89% | $66.66B | May 15, 2025 | — held |
UBS ASSET MANAGEMENT AMERICAS INC pharmaceutical preparations | 4.79M | 3.56% | 3.56% | $60.96B | May 19, 2025 | ▲ 2.77M |
FMR LLC pharmaceutical preparations | 3.32M | 2.46% | 2.46% | $42.23B | May 12, 2025 | ▼ 1.79M |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.95M | 2.19% | 2.19% | $37.60B | May 13, 2025 | ▼ 4.6K |
SIREN, L.L.C. pharmaceutical preparations | 2.67M | 1.99% | 1.99% | $34.01B | May 23, 2025 | ▼ 231.8K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 2.53M | 1.88% | 1.88% | $32.22B | May 14, 2025 | ▲ 21.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
26
Increased
+13.60M shares3
New Positions
first time holders17
Decreased
−5.06M shares0
Sold Out
fully exitedNet shares change (top 50)
+8.55M
+13.60M / −5.06M
Net new holders
+12
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ARWR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
5
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lu Hongbo director | May 12, 2026 | Sale | 2,970 | $76.88 | $228.3K | 52.0K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Apr 22, 2026 | Sale | 3,208 | $70.11 | $224.9K | 172.8K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Apr 22, 2026 | Sale | 1,157 | $70.45 | $81.5K | 171.6K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Apr 22, 2026 | Sale | 8,730 | $71.92 | $627.9K | 162.9K | Form 4 ↗ |
Hamilton James C Chief Medical Officer | Apr 23, 2026 | Sale | 10,000 | $75.00 | $750.0K | 227.0K | Form 4 ↗ |
Hamilton James C Chief Medical Officer | Mar 5, 2026 | Sale | 10,000 | $64.19 | $641.9K | 237.0K | Form 4 ↗ |
Hamilton James C Chief Medical Officer | Jan 6, 2026 | Award | 75,000 | — | — | 247.0K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Jan 6, 2026 | Award | 75,000 | — | — | 176.2K | Form 4 ↗ |
O'Brien Patrick COO | Jan 6, 2026 | Award | 75,000 | — | — | 547.4K | Form 4 ↗ |
O'Brien Patrick COO | Jan 6, 2026 | Gift | 540 | — | — | 474.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Arrowhead Pharmaceuticals, Inc. (ARWR) is primarily owned by institutional investors, who hold approximately 74.7% of total shares outstanding. Company insiders own approximately 12.83%, while retail and public investors account for the remaining 12.44%.
The largest institutional shareholder of Arrowhead Pharmaceuticals, Inc. is BLACKROCK, INC., holding approximately 19.93 million shares — equal to 14.82% of outstanding shares — as of March 31, 2025.
A total of 280 institutional investors currently hold ARWR stock, with a combined institutional value of approximately $1.34 billion as of the most recent 13F filing period.
Frequently asked questions
ARWR ownershipArrowhead Pharmaceuticals, Inc. (ARWR) is primarily owned by institutional investors, who hold approximately 74.7% of shares. The largest shareholder is BLACKROCK, INC. with a 14.82% stake. Company insiders hold 12.83%. Data sourced from SEC Form 13F as of March 31, 2025.